Rhythm Pharmaceuticals (RYTM) Finished Goods (2021 - 2025)

Rhythm Pharmaceuticals (RYTM) has reported Finished Goods for 5 consecutive years, with $14.5 million the latest figure, recorded in Q3 2025.

• In Q3 2025, Finished Goods rose 80.97% year-over-year to $14.5 million; the TTM figure through Sep 2025 stood at $14.5 million (up 80.97% YoY), while the FY2024 annual figure was $10.7 million, up 270.12% from the prior year.
• Finished Goods improved to $14.5 million in Q3 2025 per RYTM's latest filing, from $13.6 million in the prior quarter.
• Across five years, Finished Goods topped out at $14.5 million in Q3 2025 and bottomed at $111000.0 in Q4 2021.
• Historically, Finished Goods has averaged $5.7 million across 5 years, with a median of $2.9 million in 2023.
• Annual changes were most pronounced in 2022 — Finished Goods soared 75.68% — and 2023, when it soared 1384.62%.
• Rhythm Pharmaceuticals' Finished Goods stood at $111000.0 in 2021, then jumped by 75.68% to $195000.0 in 2022, then jumped by 1384.62% to $2.9 million in 2023, then soared by 270.12% to $10.7 million in 2024, then surged by 35.71% to $14.5 million in 2025.
• Business Quant data shows RYTM's Finished Goods at $14.5 million in Q3 2025, $13.6 million in Q2 2025, and $12.6 million in Q1 2025.